A New Cyclic Lipopeptide Antibiotic, Enamidonin Sir: Wehave been screening microbial fermentation for inhibitors of mitogenic activity of epidermal growth factor1?2).
During the screening, a new lipopeptide antibiotic, enamidonin ( Fig. 1) adjusted to pH 7.0 before sterilization. A culture broth (5 liters) was filtered and the mycelial cake was extracted with 70% aqueous acetone. After removal of acetone, the aqueous residue was extracted twice with 5 liters of ethyl acetate. The extracts were combined and concentrated in vacuo to yield 0.3 g ofa syrup. The syrupy residue was applied to a silica gel column (6x 90cm) equilibrated with chloroform. The column was eluted stepwise with chloroform-methanol (50: 1, 10: 1, 5: 1 and 1 : 1). Active fractions eluted with solvents 5: 1 to 1 : 1 were combined and concentrated in vacuo to yield 60mg of a white powder. This was further purified by chromatography on a Sephadex LH-20 column with chloroform-methanol (1 : 1). A white powder (7.2mg) Fig. 3 . The' UV absorption spectrum in MeOHshowed the following maxima; /lmaxnm (e) in MeOH; 223 (7, 760) and 302 (18,890) (Fig.  4) . The IR spectrum is shown in Fig. 5 . acid and (2£;4£;9£> 1 3-hydroxytetradeca-2,4,9-trienoic acid moieties were revealed. Connectivities of the partial structures and four aminoacid residues were established by HMBCand NOEdata. into Balb/MK cells at the concentration of 10/ig/ml (IC50).
The antibiotic also reversed the transformed morphology ofsrcfs-NRK to the normal flat morphology at the concentration of 10/^g/ml (ED50). Enamidonin was not inhibitory to fungi and bacteria tested on a conventional paper disk-agar method at the concentration 4/zg/disk. Detailed biological activity and the mechanism of action studies of enamidonin are in progress.
